サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1611040

バイオ医薬品サードパーティロジスティクスの市場規模、シェア、動向分析レポート：サプライチェーン別、サービスタイプ別、地域別、セグメント予測、2025年～2030年

Biopharmaceutical Third-party Logistics Market Size, Share & Trends Analysis Report By Supply Chain (Cold Chain Logistics, Non-cold Chain Logistics), By Service Type (Transportation, Warehousing & Storage), By Region, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 160 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.96円
バイオ医薬品サードパーティロジスティクスの市場規模、シェア、動向分析レポート：サプライチェーン別、サービスタイプ別、地域別、セグメント予測、2025年～2030年
出版日: 2024年11月18日
発行: Grand View Research
ページ情報: 英文 160 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

バイオ医薬品サードパーティロジスティクス市場の成長と動向

Grand View Research, Inc.の最新レポートによると、世界のバイオ医薬品サードパーティロジスティクス市場規模は2030年までに2,090億米ドルに達すると予測されています。

同市場は2025～2030年にかけてCAGR 6.58％で成長すると予測されています。様々な地域で生物製剤を輸送するための温度管理されたロジスティクスサービスに対する需要が増加していることや、バイオ医薬品企業の販売力向上のための流通網が拡大していることが、市場成長を促進する要因となっています。新興国における自動保管・検索システムの採用の高まりは、製薬ロジスティクス企業の間で進行中の動向であり、大きな牽引力となっています。

さらに、低分子医薬品からワクチンや生物製剤を中心とするバイオ医薬品への移行動向も市場を牽引すると予測されます。これらの低分子医薬品は温度に敏感な製品であるため、温度管理された輸送・保管の需要が高まり、市場成長の要因となっています。技術的進歩は市場成長を促進する主要要因の一つです。モバイルクラウドソリューション、倉庫ロボット工学、データマイニングなどの技術は、3PL空間全体を変えてきました。これらの先端技術の助けを借りて、3PL企業は輸送中に製品に必要な温度を維持することができます。

これにより、製品の複雑さや人的ミスを減らすことができます。ほとんどのバイオ医薬品は非常に温度に敏感であるため、必要な温度で保管する必要があります。このような製品には、配送までモニタリングするための追跡装置が必要です。例えば、2023年5月、Tridentifyは、コールドチェーンで輸送される製品の安定性と残存賞味期限を継続的に追跡する革新的な機能を備えたリアルタイムコールドチェーンモニタリングシステムを発売しました。このシステムは、医薬品の安定性と残存賞味期限をリアルタイムで詳細に把握できるため、企業の業務モニタリングと安定性予算の管理方法に革命をもたらすと考えられます。

さらに、環境への配慮とコストにより、商業製品の輸送手段は、航空輸送から海上輸送へ、道路輸送はトラックから複合一貫輸送（鉄道とトラックの両方）へと、少しずつシフトしています。複合一貫輸送は、二酸化炭素排出量を削減するために、これらの製薬会社が主に利用しています。現在進行中の動向を見ると、製薬メーカーはコストとリスク要因を減らすために海上輸送にシフトしています。コールドチェーン製品については、各社は依然として航空輸送を好んでいます。しかし、一部の大手製薬会社は、コールドチェーン製品を含め、製品の70%を海上輸送で輸送することを計画しています。

バイオ医薬品サードパーティロジスティクス市場レポートハイライト

  • 2024年、非コールドチェーンロジスティクスセグメントは、温度管理を必要としない医薬品の大量販売により、売上高で79.7%の最大シェアを占めました。
  • コールドチェーンロジスティクスセグメントは、細胞療法、ワクチン、検査キットなどの生物製剤の需要により、予測期間中にCAGR 9.40%を記録すると予想されています。
  • 倉庫・保管セグメントは2024年に43.3%の最大シェアを占めました。輸送セグメントも、企業の内部能力の不足により、2024年に大きな収益シェアを占めました。
  • 北米は、バイオ医薬品の輸出入の増加により、2024年に42.53%以上の最大の収益シェアを占めました。
  • アジア太平洋は、高齢化による医薬品の採用と、ブランドメーカーからジェネリックメーカーへの医薬品販売のシフトにより、予測期間中に最速のCAGR 7.4%を記録すると予想されています。
  • 主要企業は、市場での存在感を高めるためにいくつかの戦略的な取り組みを行っています。例えば、2021年2月、Kuehne+Nagelは中国最大の非国営医薬品流通企業Jointownとパートナーシップを締結し、中国における医療＆医薬品ロジスティクスの足跡を強化しています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 バイオ医薬品サードパーティロジスティクス市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 関連/補助的な市場展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
    • 市場機会分析
    • 市場課題分析
  • 市場分析ツール
    • ポーターのファイブフォース分析
    • PESTEL分析
    • COVID-19の影響分析

第4章 バイオ医薬品サードパーティロジスティクス市場：サプライチェーン、推定・動向分析

  • セグメントダッシュボード
  • 世界のバイオ医薬品サードパーティロジスティクス市場、サプライチェーンの変動分析
  • 世界のバイオ医薬品サードパーティロジスティクスの規模と動向分析、サプライチェーン別、2018～2030年
  • コールドチェーンロジスティクス
  • 非コールドチェーンロジスティクス

第5章 バイオ医薬品サードパーティロジスティクス市場：サービスタイプ、推定・動向分析

  • セグメントダッシュボード
  • 世界のバイオ医薬品サードパーティロジスティクス市場、サービスタイプの変動分析
  • 世界のバイオ医薬品サードパーティロジスティクスの規模と動向分析、サービスタイプ別、2018～2030年
  • 輸送
    • 航空貨物
    • 海上輸送
    • 陸路
  • 倉庫・保管
  • その他

第6章 バイオ医薬品サードパーティロジスティクス市場：地域別、推定・動向分析

  • 地域別市場シェア分析、2024年と2030年
  • 地域別市場ダッシュボード
  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • 英国
    • ドイツ
    • フランス
    • イタリア
    • スペイン
    • デンマーク
    • スウェーデン
    • ノルウェー
  • アジア太平洋
    • 日本
    • 中国
    • インド
    • オーストラリア
    • 韓国
    • タイ
  • ラテンアメリカ
    • ブラジル
    • アルゼンチン
  • 中東・アフリカ
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦
    • クウェート

第7章 競合情勢

  • 企業分類
  • 企業市況分析、2024年
  • 企業プロファイル
    • DHL International GmbH
    • SF Express
    • FedEx
    • United Parcel Service of America, Inc.
    • Cencora, Inc
    • DB Schenker
    • Kuehne and Nagel
    • Kerry Logistics Network Limited
    • Agility Public Warehousing Company KSCP
図表

List of Tables

  • Table 1 List of Tables
  • Table 2 List of Secondary Sources
  • Table 3 List of Abbreviations
  • Table 4 Global Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 5 Global Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 6 Global Biopharmaceutical Third-Party Logistics, by Region, 2018 - 2030 (USD Million)
  • Table 7 North America Biopharmaceutical Third-Party Logistics, by Country, 2018 - 2030 (USD Million)
  • Table 8 North America Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 9 North America Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 10 U.S. Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 11 U.S. Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 12 Canada Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 13 Canada Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 14 Mexico Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 15 Mexico Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 16 Europe Biopharmaceutical Third-Party Logistics, by Country, 2018 - 2030 (USD Million)
  • Table 17 Europe Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 18 Europe Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 19 UK Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 20 UK Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 21 Germany Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 22 Germany Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 23 France Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 24 France Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 25 Italy Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 26 Italy Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 27 Spain Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 28 Spain Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 29 Denmark Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 30 Denmark Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 31 Sweden Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 32 Sweden Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 33 Norway Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 34 Norway Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 35 Asia Pacific Biopharmaceutical Third-Party Logistics, by Country, 2018 - 2030 (USD Million)
  • Table 36 Asia Pacific Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 37 Asia Pacific Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 38 Japan Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 39 Japan Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 40 China Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 41 China Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 42 India Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 43 India Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 44 Thailand Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 45 Thailand Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 46 South Korea Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 47 South Korea Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 48 Australia Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 49 Australia Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 50 Latin America Biopharmaceutical Third-Party Logistics, by Country, 2018 - 2030 (USD Million)
  • Table 51 Latin America Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 52 Latin America Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 53 Brazil Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 54 Brazil Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 55 Argentina Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 56 Argentina Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 57 Middle East & Africa Biopharmaceutical Third-Party Logistics, by Country, 2018 - 2030 (USD Million)
  • Table 58 Middle East & Africa Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 59 Middle East & Africa Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 60 South Africa Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 61 South Africa Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 62 Saudi Arabia Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 63 Saudi Arabia Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 64 UAE Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 65 UAE Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Biopharmaceutical Third-Party Logistics, by Supply Chain, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Biopharmaceutical Third-Party Logistics, by Service Type, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Information procurement
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value chain-based sizing & forecasting
  • Fig. 7 QFD modelling for market share assessment
  • Fig. 8 Market formulation & validation
  • Fig. 9 Biopharmaceutical Third-Party Logistics Market revenue, 2018 - 2030 (USD Million)
  • Fig. 10 Biopharmaceutical Third-Party Logistics Market snapshot
  • Fig. 11 Biopharmaceutical Third-Party Logistics Market driver impact
  • Fig. 12 Biopharmaceutical Third-Party Logistics Market restraint impact
  • Fig. 13 Biopharmaceutical Third-Party Logistics Market: Supply Chain takeaways (USD Million)
  • Fig. 14 Biopharmaceutical Third-Party Logistics Market: Supply Chain movement analysis
  • Fig. 15 Cold Chain Logistics market, 2018 - 2030 (USD Million)
  • Fig. 16 Non-cold Chain Logistics market, 2018 - 2030 (USD Million)
  • Fig. 17 Biopharmaceutical Third-Party Logistics Market: Service Type takeaways (USD Million)
  • Fig. 18 Biopharmaceutical Third-Party Logistics Market: Service Type movement analysis
  • Fig. 19 Transportation market, 2018 - 2030 (USD Million)
  • Fig. 20 Air Freight market, 2018 - 2030 (USD Million)
  • Fig. 21 Sea Freight market, 2018 - 2030 (USD Million)
  • Fig. 22 Overland market, 2018 - 2030 (USD Million)
  • Fig. 23 Warehousing and Storage market, 2018 - 2030 (USD Million)
  • Fig. 24 Other Services market, 2018 - 2030 (USD Million)
  • Fig. 25 Regional marketplace: Key takeaways
  • Fig. 26 Regional outlook, 2024 & 2030
  • Fig. 27 North America Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 28 U.S. Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 29 Canada Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 30 Mexico Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 31 Europe Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 32 UK Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 33 Germany Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 34 France Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 35 Italy Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 36 Spain companion animal Health market, 2018 - 2030 (USD Million)
  • Fig. 37 Sweden Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 38 Denmark Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 39 Norway Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 40 Asia Pacific Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 41 Japan Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 42 China Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 43 India Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 44 Thailand Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 45 South Korea Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 46 Australia Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 47 Latin America Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 48 Brazil Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 49 Argentina Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 50 Middle East & Africa Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 51 South Africa Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 52 Saudi Arabia Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 53 UAE Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 54 Kuwait Biopharmaceutical Third-Party Logistics Market, 2018 - 2030 (USD Million)
  • Fig. 55 Market participant categorization
目次
Product Code: GVR-2-68038-773-5

Biopharmaceutical Third-party Logistics Market Growth & Trends:

The global biopharmaceutical third-party logistics market size is anticipated to reach USD 209.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 6.58% from 2025 to 2030. Increasing demand for temperature-controlled logistic services to transport biologics in various regions and growing distribution networks of biopharmaceutical companies to improve their sales are factors driving the market growth. The rising adoption of automated storage and retrieval systems in emerging countries is an ongoing trend among pharmaceutical logistics companies that has gained significant traction.

Furthermore, the trend of shifting from small-molecule drugs to biopharmaceuticals, mainly vaccines and biologics, is projected to drive the market. Since, these small molecule drugs are temperature-sensitive products, demand for temperature-controlled transportation and storage increases and thus, is responsible for the market growth. Technological advancements are among the main factors drivingmarket growth. Technologies, such as mobile cloud solutions, warehouse robotics, and data mining, have changed the overall 3PL space. With the help of these advanced technologies, 3PL companies can maintain the required temperatures for products during transportation.

This will help in reducing complexities in products and human errors. Most biopharmaceutical products are very temperature-sensitive and hence should be stored at the required temperatures. These products require a tracking device for monitoring until delivery. For instance, in May 2023, Tridentify launched a real-time cold chain monitoring system with an innovative feature for continuously tracking the stability and remaining shelf life of products transported in the cold chain. It offers a thorough view of the stability and remaining shelf-life of pharmaceutical products in real-time, which will revolutionize the way companies monitor their operations and manage their stability budgets.

In addition, environmental concerns and costs have caused a slight shift in the means of transport used for commercial products, moving from airway to seaway shipping and in roadways from truck to intermodal (both rail and truck) transport. Intermodal transport is majorly used by these pharmaceutical companies to reduce their carbon footprint. The ongoing trend shows that pharmaceutical manufacturers have shifted to sea freight to reduce the cost and risk factors. Although for cold chain products, the companies still prefer air freight. However, some of the large pharmaceutical companies are planning to transport 70% of their products via ocean freight including cold chain products.

Biopharmaceutical Third-party Logistics Market Report Highlights:

  • In 2024, the non-cold chain logistics segment held the largest share of 79.7% in terms of revenue owing to the sales of a large number of drugs that do not require any temperature control.
  • The cold chain logistics segment is expected to register a CAGR of 9.40% over the forecast period owing to the demand for biologics, such as cellular therapies, vaccines, and test kits.
  • The warehousing and storage segment held the largest share of 43.3% in 2024. The transportation segment also held a significant revenue share in 2024 due to the lack of internal capabilities of companies.
  • North America held the largest revenue share of over 42.53% in 2024 owing to the rise in imports and exports for biopharmaceutical in the country.
  • Asia Pacific is expected to register the fastest CAGR of 7.4% over the forecast period owing to the adoption of medicines from the aging population and the shift of drug sales from brand manufacturers to generic.
  • The key players are undertaking several strategic initiatives to strengthen their market presence. For instance, in February 2021, Kuehne+Nagel entered into a partnership with China's largest non-state-owned pharma distribution company, Jointown, to enhance its footprint in healthcare & pharmaceutical logistics in China.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Market Formulation & Validation
  • 1.6. Model Details
    • 1.6.1. Commodity Flow Analysis
    • 1.6.2. Bottom-up Approach
  • 1.7. List of Secondary Sources
  • 1.8. List of Abbreviations
  • 1.9. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Biopharmaceutical Third-Party Logistics Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook.
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Technological advancements in logistics
      • 3.2.1.2. Growing applications of reverse logistics in biopharmaceutical industry
      • 3.2.1.3. Rising demand for cold chain logistics
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. Compliance issues while outsourcing
      • 3.2.2.2. Stringent regulatory framework
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenges Analysis
  • 3.3. Market Analysis Tools
    • 3.3.1. Porter's Five Forces Analysis
    • 3.3.2. PESTEL Analysis
    • 3.3.3. COVID-19 Impact Analysis

Chapter 4. Biopharmaceutical Third-Party Logistics Market: Supply Chain Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Global Biopharmaceutical Third-Party Logistics Market; Supply Chain Movement Analysis
  • 4.3. Global Biopharmaceutical Third-Party Logistics Size & Trend Analysis, by Supply Chain, 2018 to 2030 (USD Million)
  • 4.4. Cold Chain Logistics
    • 4.4.1. Cold Chain Logistics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Non-cold Chain Logistics
    • 4.5.1. Non-cold Chain Logistics market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Biopharmaceutical Third-Party Logistics Market: Service Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Global Biopharmaceutical Third-Party Logistics Market; Service Type Movement Analysis
  • 5.3. Global Biopharmaceutical Third-Party Logistics Size & Trend Analysis, by Service Type, 2018 to 2030 (USD Million)
  • 5.4. Transportation
    • 5.4.1. Transportation market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.2. Air Freight
      • 5.4.2.1. Air freight market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.3. Sea Freight
      • 5.4.3.1. Sea freight market estimates and forecasts 2018 to 2030 (USD Million)
    • 5.4.4. Overland
      • 5.4.4.1. Overland market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Warehousing and Storage
    • 5.5.1. Warehousing and storage market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Other Services
    • 5.6.1. Other services market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Biopharmaceutical Third-Party Logistics Market: Regional Estimates & Trend Analysis

  • 6.1. Regional Market Share Analysis, 2024 & 2030
  • 6.2. Regional Market Dashboard
  • 6.3. North America
    • 6.3.1. North America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.3.2. U.S.
      • 6.3.2.1. Key country dynamics
      • 6.3.2.2. Competitive scenario
      • 6.3.2.3. Regulatory framework
      • 6.3.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.3. Canada
      • 6.3.3.1. Key country dynamics
      • 6.3.3.2. Competitive scenario
      • 6.3.3.3. Regulatory framework
      • 6.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.3.4. Mexico
      • 6.3.4.1. Key country dynamics
      • 6.3.4.2. Competitive scenario
      • 6.3.4.3. Regulatory framework
      • 6.3.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.4. Europe
    • 6.4.1. Europe Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.4.2. UK
      • 6.4.2.1. Key country dynamics
      • 6.4.2.2. Competitive scenario
      • 6.4.2.3. Regulatory framework
      • 6.4.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.3. Germany
      • 6.4.3.1. Key country dynamics
      • 6.4.3.2. Competitive scenario
      • 6.4.3.3. Regulatory framework
      • 6.4.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.4. France
      • 6.4.4.1. Key country dynamics
      • 6.4.4.2. Competitive scenario
      • 6.4.4.3. Regulatory framework
      • 6.4.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.5. Italy
      • 6.4.5.1. Key country dynamics
      • 6.4.5.2. Competitive scenario
      • 6.4.5.3. Regulatory framework
      • 6.4.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.6. Spain
      • 6.4.6.1. Key country dynamics
      • 6.4.6.2. Competitive scenario
      • 6.4.6.3. Regulatory framework
      • 6.4.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.7. Denmark
      • 6.4.7.1. Key country dynamics
      • 6.4.7.2. Competitive scenario
      • 6.4.7.3. Regulatory framework
      • 6.4.7.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.8. Sweden
      • 6.4.8.1. Key country dynamics
      • 6.4.8.2. Competitive scenario
      • 6.4.8.3. Regulatory framework
      • 6.4.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.4.9. Norway
      • 6.4.9.1. Key country dynamics
      • 6.4.9.2. Competitive scenario
      • 6.4.9.3. Regulatory framework
      • 6.4.9.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Asia Pacific
    • 6.5.1. Asia Pacific Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.5.2. Japan
      • 6.5.2.1. Key country dynamics
      • 6.5.2.2. Competitive scenario
      • 6.5.2.3. Regulatory framework
      • 6.5.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.3. China
      • 6.5.3.1. Key country dynamics
      • 6.5.3.2. Competitive scenario
      • 6.5.3.3. Regulatory framework
      • 6.5.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.4. India
      • 6.5.4.1. Key country dynamics
      • 6.5.4.2. Competitive scenario
      • 6.5.4.3. Regulatory framework
      • 6.5.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.5. Australia
      • 6.5.5.1. Key country dynamics
      • 6.5.5.2. Competitive scenario
      • 6.5.5.3. Regulatory framework
      • 6.5.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.6. South Korea
      • 6.5.6.1. Key country dynamics
      • 6.5.6.2. Competitive scenario
      • 6.5.6.3. Regulatory framework
      • 6.5.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.5.7. Thailand
      • 6.5.7.1. Key country dynamics
      • 6.5.7.2. Competitive scenario
      • 6.5.7.3. Regulatory framework
      • 6.5.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Latin America
    • 6.6.1. Latin America Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.6.2. Brazil
      • 6.6.2.1. Key country dynamics
      • 6.6.2.2. Competitive scenario
      • 6.6.2.3. Regulatory framework
      • 6.6.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.6.3. Argentina
      • 6.6.3.1. Key country dynamics
      • 6.6.3.2. Competitive scenario
      • 6.6.3.3. Regulatory framework
      • 6.6.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. MEA
    • 6.7.1. MEA Market Estimates and Forecasts 2018 to 2030 (USD Million)
    • 6.7.2. South Africa
      • 6.7.2.1. Key country dynamics
      • 6.7.2.2. Competitive scenario
      • 6.7.2.3. Regulatory framework
      • 6.7.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.3. Saudi Arabia
      • 6.7.3.1. Key country dynamics
      • 6.7.3.2. Competitive scenario
      • 6.7.3.3. Regulatory framework
      • 6.7.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.4. UAE
      • 6.7.4.1. Key country dynamics
      • 6.7.4.2. Competitive scenario
      • 6.7.4.3. Regulatory framework
      • 6.7.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 6.7.5. Kuwait
      • 6.7.5.1. Key country dynamics
      • 6.7.5.2. Competitive scenario
      • 6.7.5.3. Regulatory framework
      • 6.7.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Company Categorization
  • 7.2. Company Market Position Analysis, 2024
  • 7.3. Company Profiles
    • 7.3.1. DHL International GmbH
      • 7.3.1.1. Company overview
      • 7.3.1.2. Financial performance
      • 7.3.1.3. Service benchmarking
      • 7.3.1.4. Strategic initiatives
    • 7.3.2. SF Express
      • 7.3.2.1. Company overview
      • 7.3.2.2. Financial performance
      • 7.3.2.3. Service benchmarking
      • 7.3.2.4. Strategic initiatives
    • 7.3.3. FedEx
      • 7.3.3.1. Company overview
      • 7.3.3.2. Financial performance
      • 7.3.3.3. Service benchmarking
      • 7.3.3.4. Strategic initiatives
    • 7.3.4. United Parcel Service of America, Inc.
      • 7.3.4.1. Company overview
      • 7.3.4.2. Financial performance
      • 7.3.4.3. Service benchmarking
      • 7.3.4.4. Strategic initiatives
    • 7.3.5. Cencora, Inc
      • 7.3.5.1. Company overview
      • 7.3.5.2. Financial performance
      • 7.3.5.3. Service benchmarking
      • 7.3.5.4. Strategic initiatives
    • 7.3.6. DB Schenker
      • 7.3.6.1. Company overview
      • 7.3.6.2. Financial performance
      • 7.3.6.3. Service benchmarking
      • 7.3.6.4. Strategic initiatives
    • 7.3.7. Kuehne and Nagel
      • 7.3.7.1. Company overview
      • 7.3.7.2. Financial performance
      • 7.3.7.3. Service benchmarking
      • 7.3.7.4. Strategic initiatives
    • 7.3.8. Kerry Logistics Network Limited
      • 7.3.8.1. Company overview
      • 7.3.8.2. Financial performance
      • 7.3.8.3. Service benchmarking
      • 7.3.8.4. Strategic initiatives
    • 7.3.9. Agility Public Warehousing Company K.S.C.P.
      • 7.3.9.1. Company overview
      • 7.3.9.2. Financial performance
      • 7.3.9.3. Service benchmarking
      • 7.3.9.4. Strategic initiatives